ClinicalTrials.gg
CompletedNCT05324124Updated Mar 21, 2025Results posted

A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants

A Phase 1 interventional study of Selpercatinib in Healthy, sponsored by Loxo Oncology, Inc.. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to learn about how food affects selpercatinib in healthy participants. The selpercatinib will be administered in fed and fasted states. Participation could last about 7 weeks.

02

Conditions studied

  • Healthy

Keywords

  • Selpercatinib
  • Food
  • Pharmacokinetics
03

In context

Lead sponsor

Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs and clinical laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the product; or of interfering with the interpretation of data.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Selpercatinib (Fasted/Fed)

    Period 1: 160 milligrams (mg) Selpercatinib administered orally on Day 1 in fasted state. Period 2: 160 mg Selpercatinib administered orally on Day 8 in fed state.

    Drug: Selpercatinib

  • Experimental
    Selpercatinib (Fed/Fasted)

    Period 1: 160 mg Selpercatinib administered orally on Day 1 in fed state. Period 2: 160 mg Selpercatinib administered orally on Day 8 in fasted state.

    Drug: Selpercatinib

Interventions

  • Administered orally.

    Also known as: LY3527723, LOXO-292

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics(PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib

    PK: AUC\[0-∞\] of Selpercatinib'

    Time frame: PK: Day 1 and Day 8: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours (h) postdose;

  2. PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib

    PK: AUC\[0-tlast\] of Selpercatinib

    Time frame: PK: Day 1 and Day 8: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours (h) postdose;

  3. PK: Maximum Concentration (Cmax) of Selpercatinib

    PK: Cmax of Selpercatinib.

    Time frame: PK: Day 1 and Day 8: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours (h) postdose;

07

Results

Posted Mar 21, 2025

Participant flow

Period 1
Participant flow — Period 1
MilestoneSelpercatinib Fasted/FedSelpercatinib Fed/Fasted
Started2323
Received one dose of study drug2323
Completed2222
Not completed11
Withdrew: Withdrawal by subject10
Withdrew: Physician decision01
Period 2
Participant flow — Period 2
MilestoneSelpercatinib Fasted/FedSelpercatinib Fed/Fasted
Started2222
Completed2222
Not completed00

Outcome measures

PrimaryPharmacokinetics(PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib

PK: AUC\[0-∞\] of Selpercatinib'

Time frame:
PK: Day 1 and Day 8: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours (h) postdose;
Reported as:
Geometric mean · nanogram * hour per milliliter (ng*hr/mL
Pharmacokinetics(PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib
nanogram * hour per milliliter (ng*hr/mLSelpercatinib Fasted (Reference)Selpercatinib Fed (Test)
Pharmacokinetics(PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib23400 ± 3222500 ± 44
Statistical analysis
  • Selpercatinib Fasted (Reference) vs Selpercatinib Fed (Test) · Ratio of geometric least squares mean: 0.952 · 90% CI 0.876 to 1.03
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib

PK: AUC\[0-tlast\] of Selpercatinib

Time frame:
PK: Day 1 and Day 8: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours (h) postdose;
Reported as:
Geometric mean · ng*hr/mL
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib
ng*hr/mLSelpercatinib Fasted (Reference)Selpercatinib Fed (Test)
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib22700 ± 3221700 ± 46
Statistical analysis
  • Selpercatinib Fasted (Reference) vs Selpercatinib Fed (Test) · Ratio of geometric least squares mean: 0.949 · 90% CI 0.869 to 1.04
PrimaryPK: Maximum Concentration (Cmax) of Selpercatinib

PK: Cmax of Selpercatinib.

Time frame:
PK: Day 1 and Day 8: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours (h) postdose;
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of Selpercatinib
nanograms per milliliter (ng/mL)Selpercatinib Fasted (Reference)Selpercatinib Fed (Test)
PK: Maximum Concentration (Cmax) of Selpercatinib1840 ± 391540 ± 45
Statistical analysis
  • Selpercatinib Fasted (Reference) vs Selpercatinib Fed (Test) · Ratio of geometric least squares mean: 0.829 · 90% CI 0.744 to 0.925

Adverse events

Collected over Screening up to 21 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
160 mg Selpercatinib Fasted0/45 (0%)0/45 (0%)29/45 (64.4%)
160 mg Selpercatinib Fed0/45 (0%)0/45 (0%)21/45 (46.7%)
Most frequent other events
Most frequent other events
Event160 mg Selpercatinib Fasted160 mg Selpercatinib Fed
Catheter site erythemaGeneral disorders12/4513/45
Catheter site painGeneral disorders10/456/45
DiarrhoeaGastrointestinal disorders7/455/45
Catheter site bruiseGeneral disorders7/454/45
HeadacheNervous system disorders6/451/45
FatigueGeneral disorders4/453/45
Catheter site swellingGeneral disorders3/453/45
Vessel puncture site bruiseGeneral disorders3/453/45

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Selpercatinib
Mean40.6 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Selpercatinib
Female10
Male36
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selpercatinib
Hispanic or Latino0
Not Hispanic or Latino46
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selpercatinib
American Indian or Alaska Native0
Asian45
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Selpercatinib
Singapore46
08

Study locations

1 site
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jun 2022, 2 months.

Results were first posted in Mar 2025, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2022
First posted
Apr 12, 2022
StartActual
Apr 19, 2022
Primary completionActual
Jun 22, 2022
CompletionActual
Jun 22, 2022
Results first posted
Mar 21, 2025
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05324124
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
Apr 19, 2022
Primary completion
Jun 22, 2022
Completion
Jun 22, 2022
Results posted
Mar 21, 2025
Last update
Mar 21, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion